No Data
Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Profit Outlook
Express News | JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $64
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $64
Express News | Apellis Pharmaceuticals Inc : JP Morgan Cuts Target Price to $64 From $72
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)
Express News | Apellis Pharmaceuticals Inc : UBS Cuts Target Price to $83 From $85